Progressive resolution of exudation from perifoveal vascular anomalous complex: A possible role of diclofenac therapy?
Diclofenac
Exudative
Optical coherence tomography angiography
PEVAC
PVAC
Perifoveal exudative vascular anomalous complex
Perifoveal vascular anomalous complex
Journal
American journal of ophthalmology case reports
ISSN: 2451-9936
Titre abrégé: Am J Ophthalmol Case Rep
Pays: United States
ID NLM: 101679941
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
30
09
2021
revised:
02
03
2022
accepted:
02
03
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
To report a case of progressive resolution of exudation in a patient affected by perifoveal vascular anomalous complex (PVAC) undergoing topical diclofenac therapy. A 74-year-old man presented to our department with visual decrease in his right eye lasting six months. Lack of clinical history of arterial hypertension, diabetes, or any other systemic or local vasculopathy, together with retinal multimodal imaging, led to the diagnosis of exudative (e)PVAC. Serial spectral-domain optical coherence tomography (SD-OCT) examinations documented a resolution of intraretinal exudation after one-month topical diclofenac therapy. Initiation of topical diclofenac was associated with resolution of exudation, therefore we hypothesize its potential role in the treatment of ePVAC.
Identifiants
pubmed: 35282605
doi: 10.1016/j.ajoc.2022.101472
pii: S2451-9936(22)00218-3
pmc: PMC8907685
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101472Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Beatrice Tombolini, Michele Cavalleri, Ilaria Zucchiatti, Lea Querques: none. Riccardo Sacconi: consultant for Bayer Shering-Pharma (Berlin, Germany), Novartis (Basel, Switzerland), Zeiss (Dublin, USA). Francesco Bandello consultant for: Alcon (Fort Worth, Texas,USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, USA). Giuseppe Querques consultant for: Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Bayer Shering-Pharma (Berlin, Germany), Heidelberg (Germany), Novartis (Basel, Switzerland), Sandoz (Berlin, Germany), Zeiss (Dublin, USA).
Références
Acta Ophthalmol. 2021 Aug;99(5):553-558
pubmed: 33210824
Neurobiol Aging. 2012 Jan;33(1):194.e1-4
pubmed: 20472327
Retina. 2021 Jan 1;41(1):162-169
pubmed: 32271275
Retina. 2019 Oct;39(10):1889-1895
pubmed: 30489449
J Fr Ophtalmol. 2011 Oct;34(8):559.e1-4
pubmed: 21550688
Am J Ophthalmol. 2020 Oct;218:59-67
pubmed: 32360340
Ophthalmic Surg Lasers Imaging Retina. 2018 Dec 1;49(12):974-978
pubmed: 30566706
Expert Opin Drug Deliv. 2015;12(11):1767-82
pubmed: 26173446
Mediators Inflamm. 2013;2013:476525
pubmed: 24227908
Am J Ophthalmol Case Rep. 2019 Apr 04;14:112-116
pubmed: 31032462
Ther Adv Ophthalmol. 2020 Sep 11;12:2515841420947930
pubmed: 32964194
Retina. 2020 Jan;40(1):80-86
pubmed: 30601390
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6
pubmed: 14688410
Am J Ophthalmol. 2017 Dec;184:137-146
pubmed: 29079450
Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):31-8
pubmed: 15720233
Semin Ophthalmol. 2013 Mar;28(2):84-7
pubmed: 23448562
Organogenesis. 2010 Jan-Mar;6(1):1-10
pubmed: 20592859